{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:01:06Z","timestamp":1767942066310,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by reduced platelet counts, leading to an increased risk of bleeding and substantial impairment patients\u2019 quality of life. Although rituximab (RTX) is commonly employed as a second-line treatment for patients with steroid-refractory or steroid-resistant ITP, its long-term efficacy as monotherapy remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy and safety of low-dose RTX (LD-RTX) in combination with thalidomide (THD) in the treatment of patients with steroid-refractory or steroid-dependent ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A total of 100 patients with ITP who failed first-line treatment at Shangqiu First People\u2019s Hospital and Funing County People\u2019s Hospital between January 2021 and January 2025 were enrolled in a randomized controlled trial. Participants were assigned to one of two groups: the LD-RTX group (ctrl-group) or the T\u2009+\u2009LD-RTX group (thal-group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall response rate in the thal-group was significantly higher than in the ctrl-group (79.17% vs. 55.32%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Among patients who achieved a therapeutic response, baseline levels of CD16\n                      <jats:sup>+<\/jats:sup>\n                      CD56\n                      <jats:sup>+<\/jats:sup>\n                      CD3\n                      <jats:sup>\u2212<\/jats:sup>\n                      natural killer (NK) cells were significantly lower in the complete remission (CR) group (78.81\u2009\u00b1\u200920.15 cells\/\u03bcL) and partial remission (PR) group (91.82\u2009\u00b1\u200928.64 cells\/\u03bcL) compared to the non-remission (NR) group (139.00\u2009\u00b1\u200942.42 cells\/\u03bcL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). In the thal-group, the absolute count of CD16\n                      <jats:sup>+<\/jats:sup>\n                      NK cells in responders (CR\u2009+\u2009PR) increased from 84.63\u2009\u00b1\u200924.85 cells\/\u03bcL at baseline to 138.71\u2009\u00b1\u200919.20 cells\/\u03bcL after 6\u2009months. In contrast, in the ctrl-group, NK cell counts increased slightly from 92.96\u2009\u00b1\u200923.17 cells\/\u03bcL to 129.73\u2009\u00b1\u200928.50 cells\/\u03bcL over the same period. Patients with lower pre-treatment levels of CD16\n                      <jats:sup>+<\/jats:sup>\n                      CD56\n                      <jats:sup>+<\/jats:sup>\n                      CD3\n                      <jats:sup>\u2212<\/jats:sup>\n                      NK cells demonstrated better therapeutic responses, and a significant post-treatment increase in NK cell counts was observed in the combination group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). ROC analysis identified a threshold of 110.5 cells\/\u03bcL for the absolute NK cell count (sensitivity: 81.6%; specificity: 100.0%) and 5.72% for the NK cell percentage (sensitivity: 65.8%; specificity: 100.0%) as predictive markers for achieving CR or PR. Lower baseline values were associated with more favorable outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of THD LD-RTX represents a promising therapeutic strategy for patients with steroid-refractory or steroid-dependent ITP. Furthermore, baseline NK cell levels may serve as a useful biomarker for predicting treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1670736","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:14:52Z","timestamp":1767935692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy of thalidomide combined with low-dose rituximab and low-dose rituximab alone in the treatment of steroid-resistant\/refractory adult patients with primary immune thrombocytopenia: an open-label trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuo","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingzhu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengfu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12288-018-1061-7","article-title":"Clinical efficacy and safety of high-dose dexamethasone plus low-dose rituximab as first-line therapy in newly diagnosed primary immune thrombocytopenia","volume":"35","author":"Zhou","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10753-020-01378-8","article-title":"Thalidomide inhibits angiogenesis via downregulation of VEGF and Angiopoietin-2 in Crohn's disease","volume":"44","author":"Wang","year":"2021","journal-title":"Inflammation"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3760\/cma.j.issn.0253-2727.2011.09.002","article-title":"Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia","volume":"32","author":"Sui","year":"2011","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.intimp.2019.04.041","article-title":"Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression","volume":"72","author":"Yang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2013-03-491555","article-title":"Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia","volume":"122","author":"Ma","year":"2013","journal-title":"Blood"},{"key":"ref10","first-page":"431","article-title":"Interpretation of Chinese guidelines for the diagnosis and treatment of primary immunothrombocytopenia in adults (2020 edition)","volume":"38","author":"Mei","year":"2021","journal-title":"J Clin Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood.2021013393","article-title":"All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP","volume":"139","author":"Wu","year":"2022","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00277-022-04784-0","article-title":"Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Ann Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1316096","article-title":"Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a Meta-analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"9992086","DOI":"10.1155\/2021\/9992086","article-title":"The efficacy and safety of different dosages of rituximab for adults with immune thrombocytopenia: a systematic review and Meta-analysis","volume":"2021","author":"Dong","year":"2021","journal-title":"Biomed Res Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1185\/03007995.2011.644849","article-title":"Selective validation of the WHO bleeding scale in patients with chronic immune thrombocytopenia","volume":"28","author":"Fogarty","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3960\/jslrt.19030","article-title":"T-cell large granular lymphocytic (LGL) leukemia consists of CD4+\/CD8dim and CD4-\/CD8+ LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis","volume":"59","author":"Kuwahara","year":"2019","journal-title":"J Clin Exp Hematop"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.2174\/138955709788452595","article-title":"Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives","volume":"9","author":"Cundari","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s12185-009-0314-5","article-title":"Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed\/refractory multiple myeloma","volume":"89","author":"Murakami","year":"2009","journal-title":"Int J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12032-025-02655-y","article-title":"Addition of thalidomide for prevention of chemotherapy-induced nausea and vomiting in the second cycle after the failure of four-drug regimen in the first cycle","volume":"42","author":"Gowda","year":"2025","journal-title":"Med Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10787-023-01193-1","article-title":"Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis","volume":"31","author":"Dsouza","year":"2023","journal-title":"Inflammopharmacology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/bjh.18818","article-title":"Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: circulating number of NK cells is associated with the response at 6\u2009months","volume":"202","author":"Rivi\u00e8re","year":"2023","journal-title":"Br J Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjh.19083","article-title":"Pathogenesis of refractory ITP: overview","volume":"203","author":"Cines","year":"2023","journal-title":"Br J Haematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2567.2010.03360.x","article-title":"Natural killer cells in human autoimmune diseases","volume":"131","author":"Schleinitz","year":"2010","journal-title":"Immunology"},{"key":"ref25","first-page":"1231","article-title":"NK cell quantity and function in patients with immune thrombocytopenia","volume":"97","author":"Zhang","year":"2017","journal-title":"Chin Med J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/cei.12279","article-title":"Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP)","volume":"176","author":"Talaat","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-019-1687-x","article-title":"CXCR5-negative natural killer cells ameliorate experimental autoimmune myasthenia gravis by suppressing follicular helper T cells","volume":"16","author":"Yang","year":"2019","journal-title":"J Neuroinflammation"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1111\/cas.14538","article-title":"Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells","volume":"111","author":"Miyazato","year":"2020","journal-title":"Cancer Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1038\/s41598-020-59542-x","article-title":"Thalidomide inhibits human iPSC Mesendoderm differentiation by modulating CRBN-dependent degradation of SALL4","volume":"10","author":"Belair","year":"2020","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"104343","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1670736\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:14:53Z","timestamp":1767935693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1670736\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1670736"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1670736","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1670736"}}